Table 2.
Clinical characteristics and GH treatments in the 23 patients who developed cancer after GH treatment
| # | Type of cancer | Died (Y/N) | Age at event or death (y)a | Sex | Diagnosis leading to GH treatment | Age at start of GH treatment (y) | Height (SD) before treatment | GH treatment duration (y) | Height (SD) at the end of treatment | Adult height (SD) | Mean GH dose (μg/kg/d) | Source of information for cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Acute leukemia | Y | 12.9 | F | GHDI | 11.1 | ‐ | 1.4 | ‐ | ‐ | ‐ | CépiDC |
| 2 | Acute leukemia | Y | 14.8 | M | GHDI | 12.7 | −2.1 | 0.8 | −1.8 | ‐ | 23.5 | CépiDC |
| 3 | Acute leukemia | Y | 16.5 | F | GHDI | 9.2 | ‐ | 1.9 | ‐ | ‐ | ‐ | CépiDC |
| 4 | Lymphoma | N | 29.0 | F | GHDI | 12.0 | −2.5 | 3.3 | −2.1 | −1.5 | 19.2 | Questionnaire |
| 5 | Lymphoma | N | 11.5 | M | GHDI | 7.0 | −1.9 | 3.7 | −1.0 | −2.1 | 17.1 | Questionnaire |
| 6 | Lymphoma | N | 24.4 | M | GHDI | 9.9 | −2.2 | 5.6 | −0.6 | ‐ | 23.4 | LLA. Questionnaire |
| 7 | Lymphoma | N | 22.4 | M | GHDI | 8.6 | −2.0 | 4.0 | −1.9 | ‐ | 21.1 | LLA. FHDD |
| 9 | Ewing sarcoma | Y | 17.3 | M | GHDI | 10.3 | −3.5 | 5.1 | −2.4 | ‐ | 24.4 | CépiDC |
| 8 | Osteosarcoma | Y | 14.4 | M | SGA | 8.5 | −3.6 | 3.0 | −2.4 | ‐ | 60.0 | CépiDC |
| 10 | Osteosarcoma | Y | 20.2 | F | GHDI | 4.5 | −2.7 | 8.2 | ‐ | ‐ | 26.6 | CépiDC |
| 11 | Osteosarcoma | N | 7.4 | M | GHDI | 6.1 | −3.3 | 1.1 | −2.9 | −3.6 | 24.1 | LLA. Questionnaire |
| 12 | Chondrosarcoma | N | 21.8 | M | GHDI | 15.8 | −1.3 | 1.2 | −0.7 | −0.7 | 26.1 | Questionnaire |
| 13 | Malignant brain tumor | N | 18.2 | M | GHDI | 2.4 | ‐ | 9.0 | ‐ | ‐ | ‐ | LLA |
| 14 | Melanoma | Y | 28.1 | M | GHDI | 11.1 | −2.6 | 6.1 | −1.8 | −2.0 | 17.3 | CépiDC |
| 15 | Melanoma | N | 31.5 | F | GHDI | 15.1 | ‐ | 1.9 | ‐ | −1.5 | ‐ | Questionnaire |
| 16 | Nasopharyngeal carcinoma | Y | 19.3 | M | GHDI | 11.2 | ‐ | 1.4 | ‐ | ‐ | ‐ | CépiDC |
| 17 | Malignant tumor of the mouth | N | 26.4 | M | GHDI | 8.5 | −2.0 | 7.1 | −0.6 | −0.9 | 21.5 | LLA. FHDD |
| 18 | Malignant tumor of the kidney | N | 29.5 | F | GHDI | 9.6 | ‐ | 2.4 | ‐ | −2.7 | ‐ | LLA. FHDD. Questionnaire |
| 19 | Malignant tumor of the testis | N | 31.6 | M | GHDI | 12.2 | ‐ | 2.0 | −1.8 | −0.9 | 15.8 | LLA. FHDD. Questionnaire |
| 20 | Malignant tumor of the testis | N | 15.0 | M | GHDI | 12.7 | −1.9 | 3.5 | −1.3 | 27.9 | Questionnaire | |
| 21 | Sweat gland carcinoma | N | 32.6 | F | GHDI | 13.9 | −2.7 | 2.5 | −2.2 | −2.3 | 28.0 | Questionnaire |
| 22 | Pulmonary carcinoma | N | 26.9 | M | GHDI | 8.0 | −1.7 | 3.7 | −1.2 | −1.7 | 17.2 | FHDD. Questionnaire |
| 23 | Malignant pancreatic tumor | N | 19.4 | M | GHDI | 8.2 | −2.2 | 6.6 | −0.5 | −1.1 | 16.7 | LLA. FHDD. Questionnaire |
LLA, long‐lasting affection; FHDD, French hospital discharge database; F, female; M, male; GHDI, idiopathic growth hormone deficiency; SGA, Born small for gestational age.
a
Age at event was used for live patients, and age at death was used for those who died.